Because HCC is a highly vascularized tumor type, inhibiting CDK5 and therefore angiogenesis, could prove a promising treatment for this tumor subtype and other highly vascularized tumors [64]. This evidence concerns the gene CDK5 and hepatocellular carcinoma.